INTRODUCTION

Various studies have shown that hypertension,\textsuperscript{1,2} through different mechanisms,\textsuperscript{3} is an important risk factor for incident atrial fibrillation (AF) which in turn increases cardiovascular risk.\textsuperscript{4}

Clinic blood pressure (BP) recording is traditionally used for diagnosis and management of hypertension. However, it has been largely reported that ambulatory BP is superior to clinic BP in predicting cardiovascular outcome.\textsuperscript{5-11}

In such a context, some studies have also evaluated whether ambulatory BP is superior to clinic BP in predicting new-onset AF.\textsuperscript{12-18} It has been reported that daytime,\textsuperscript{16-18} nighttime,\textsuperscript{15-18} and 24-h BP\textsuperscript{13-18} are independent predictors of new-onset AF and that these ambulatory BP measures tend to be superior to clinic BP in predicting future AF. However, as there is still little information on this subject,\textsuperscript{19} pooling all available evidence could allow for a more robust assessment of the association between AF and clinic and ambulatory BP.
The aim of this study was to perform a meta-analysis of studies evaluating the association of clinic and daytime, nighttime, and 24-h BP with the occurrence of new-onset AF.

2 | METHODS

The study was performed in accordance with the recommendations of the Meta-analysis of Observational Studies in Epidemiology Group. Original studies were approved by the institutional review committees and patients gave informed consent.

2.1 | Search strategy

We conducted a literature search through PubMed, Web of science, and Cochrane Library for articles evaluating the occurrence of new-onset AF according to clinic, daytime, nighttime, and 24-h BP up to January 15, 2021. The terms used to identify studies were “clinic blood pressure,” “ambulatory blood pressure,” “daytime blood pressure,” “diurnal blood pressure,” “nighttime blood pressure,” “nocturnal blood pressure,” “twenty-four-hour blood pressure,” “24-h blood pressure,” and “atrial fibrillation.” Two reviewers (FC and AMP) independently screened titles and abstracts to identify eligible studies. Disagreement between the two reviewers was resolved by a third reviewer. Reference lists of included articles were also examined for additional studies. If necessary, supplementary data were obtained through personal contact with the investigators of the selected studies.

2.2 | Eligibility criteria

Inclusion criteria for entry in the present meta-analysis were as follows: (a) full-text paper published in a peer-reviewed journal; (b) any language of publication; (c) study on adult population; (d) prospective study; (e) follow-up of at least 1 year; (f) use of ambulatory BP monitoring; (g) assessment of new-onset AF; (h) availability of...
adjusted hazard ratio (HR) and 95% confidence interval (CI) for new-onset AF according to increments of clinic and/or daytime, nighttime, and 24-h BP.

2.3 Study selection, data extraction, and quality evaluation

The first literature search identified 302 studies. Of these, 7 were eligible after revision of titles and abstracts. Two studies were excluded because they did not report separate data for clinic and/or daytime, nighttime and 24-h BP. Thus, 5 studies were included. Selection of publications is summarized in Figure 1.

Two reviewers (FC and AMP) independently extracted relevant data from selected studies. Disagreement between the two reviewers was resolved by a third reviewer.

The quality of included studies was evaluated using the Newcastle-Ottawa scale for assessable items.

2.4 Statistical analysis

To address confounding from other risk factors, we used the adjusted HR and 95% CI of the individual studies to calculate the overall adjusted HR and 95% CI. For Pierdomenico and colleagues, HRs and 95% CIs for clinic, daytime, and nighttime BP were recalculated from the original database. For Perkioðaki and colleagues, values of log hazard ratio and standard error were extrapolated from published HRs and 95% CIs by using the Comprehensive Meta-Analysis software and normalized to 1 unit; then, HRs and 95% CIs were expressed per 10 mmHg increments of BP by means of a dedicated software, and finally, they were used for the meta-analysis. We used the random effects model. Tests of heterogeneity were performed using the Cochrane Q statistic and I² statistic. Subgroup meta-analysis, which is equivalent to meta-regression with categorical (or categorized) variables, was also performed to analyze potential sources of heterogeneity. Individual studies were removed one at a time to evaluate the influence of that study on the pooled estimate. Usually, tests for funnel plot asymmetry are used when approximately 10 studies are included in the meta-analysis, because when there are few studies the power of the tests is too low to distinguish chance from real asymmetry; thus, due to the relatively low number of studies available in the literature, the above-mentioned statistical approach was not performed. Statistical significance was defined as p < .05 (2-tailed tests). Analyses were done using the Comprehensive Meta-Analysis software version 2 (Biostat).

3 RESULTS

Main characteristics of selected studies are reported in Table 1. The pooled population consisted of 7224 patients who experienced 444 cases of AF. The majority of the studies, except one, included subjects aged ≥40 years. Mean follow-up ranged from 6 to 16 years. Four studies included Caucasian individuals, and one study included mainly Hispanic subjects. One study evaluated untreated hypertensive patients, one study assessed treated hypertensive patients, and three studies comprised subjects with normotension and hypertension in different percentages.

Covariates included in the multivariate analysis of selected studies are reported in Table 2. Though there were some differences across the studies, a set of covariates including the main determinants of AF was used in multivariate analysis in the various studies.

According to the Newcastle-Ottawa scale, for assessable items, all the included studies were of good quality (Table S1).

Figure 2 gives the adjusted HR and 95% CI of the individual studies and of the overall analysis. The overall adjusted HR (95% CI) was 1.05 (0.98-1.13), 1.19 (1.11-1.27), 1.18 (1.11-1.26), and 1.23 (1.14-1.32), per 10-mmHg increment in clinic, daytime, nighttime, and 24-h systolic BP, respectively. The degree of heterogeneity of the HR estimates across the studies (Q and I-squared statistics) were minimal. To further explore this aspect, subgroup meta-analysis was

| Study                | Covariates                                                                 |
|---------------------|-----------------------------------------------------------------------------|
| Pierdomenico et al  | Age, sex, family history of premature CV disease, smoking habit, BMI, LDL-cholesterol, creatinine, DM, LA enlargement or LVH, nondipping, antihypertensive drug class at follow-up |
| Perkioðaki et al    | Age, sex, BMI, height, smoking, alanine aminotransferase, uric acid, glucose |
| Tikhonoff et al     | Age, sex, BMI, serum cholesterol, tobacco and alcohol use, history of CV disease and DM and antihypertensive drug treatment |
| Matsumoto et al     | Age, sex, race, and hypertension status at baseline                           |
| Coccina et al       | Age, BMI, family history of CV disease, DM, eGFR, LVH, LA enlargement, ALVSD, number of antihypertensive drugs |

Abbreviations: ALVSD, asymptomatic left ventricular systolic dysfunction; BMI, body mass index; CV, cardiovascular; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; LA, left atrial; LVH left ventricular hypertrophy.
## Risk of New-Onset Atrial Fibrillation
(Per 10-mmHg Increment in Clinic Systolic Blood Pressure)

| Study name                  | Hazard ratio | Statistics for each study | Hazard ratio and 95% CI |
|-----------------------------|--------------|---------------------------|------------------------|
|                             |              | Lower limit | Upper limit | Z-Value | p-Value |
| Pierdomenico et al. 2008    | 0.990        | 0.768       | 1.276      | -0.078  | 0.938   |
| Tikhonoff et al. 2018       | 1.100        | 0.987       | 1.226      | 1.721   | 0.085   |
| Matsunoto et al. 2021       | 0.940        | 0.810       | 1.090      | -0.817  | 0.414   |
| Coccina et al. 2021         | 1.090        | 0.968       | 1.227      | 1.423   | 0.155   |
|                             | 1.050        | 0.976       | 1.131      | 1.304   | 0.192   |

Q=3.42; P=0.33
I-squared=12.268

## (Per 10-mmHg Increment in Daytime Systolic Blood Pressure)

| Study name                  | Hazard ratio | Statistics for each study | Hazard ratio and 95% CI |
|-----------------------------|--------------|---------------------------|------------------------|
|                             |              | Lower limit | Upper limit | Z-Value | p-Value |
| Pierdomenico et al. 2008    | 1.280        | 0.993       | 1.649      | 1.909   | 0.056   |
| Perkiomaki et al. 2017      | 1.100        | 0.956       | 1.265      | 1.335   | 0.182   |
| Tikhonoff et al. 2018       | 1.180        | 1.018       | 1.368      | 2.199   | 0.028   |
| Matsunoto et al. 2021       | 1.210        | 1.043       | 1.404      | 2.514   | 0.012   |
| Coccina et al. 2021         | 1.230        | 1.094       | 1.383      | 3.468   | 0.001   |
|                             | 1.189        | 1.114       | 1.270      | 5.168   | 0.000   |

Q=1.90; P=0.75
I-squared=0.000

## (Per 10-mmHg Increment in Nighttime Systolic Blood Pressure)

| Study name                  | Hazard ratio | Statistics for each study | Hazard ratio and 95% CI |
|-----------------------------|--------------|---------------------------|------------------------|
|                             |              | Lower limit | Upper limit | Z-Value | p-Value |
| Pierdomenico et al. 2008    | 1.300        | 1.050       | 1.610      | 2.406   | 0.016   |
| Perkiomaki et al. 2017      | 1.150        | 1.006       | 1.314      | 2.052   | 0.040   |
| Tikhonoff et al. 2018       | 1.160        | 1.016       | 1.325      | 2.192   | 0.028   |
| Matsunoto et al. 2021       | 1.220        | 1.070       | 1.391      | 2.979   | 0.003   |
| Coccina et al. 2021         | 1.160        | 1.029       | 1.308      | 2.419   | 0.016   |
|                             | 1.162        | 1.111       | 1.257      | 3.312   | 0.000   |

Q=1.32; P=0.86
I-squared=0.000

## (Per 10-mmHg Increment in 24-hour Systolic Blood Pressure)

| Study name                  | Hazard ratio | Statistics for each study | Hazard ratio and 95% CI |
|-----------------------------|--------------|---------------------------|------------------------|
|                             |              | Lower limit | Upper limit | Z-Value | p-Value |
| Pierdomenico et al. 2008    | 1.320        | 1.047       | 1.665      | 2.345   | 0.019   |
| Perkiomaki et al. 2017      | 1.190        | 1.023       | 1.384      | 2.256   | 0.024   |
| Tikhonoff et al. 2018       | 1.230        | 1.055       | 1.434      | 2.649   | 0.008   |
| Matsunoto et al. 2021       | 1.240        | 1.069       | 1.439      | 2.839   | 0.005   |
| Coccina et al. 2021         | 1.220        | 1.062       | 1.402      | 2.802   | 0.005   |
|                             | 1.229        | 1.145       | 1.318      | 5.740   | 0.000   |

Q=0.56; P=0.97
I-squared=0.000
performed according to mean age at entry and prevalence of hypertension in the studied populations (Table 3). Though some differences were observed, there was no evidence of heterogeneity with respect to either.

Sensitivity analysis (Figure 3) indicated that none of the studies had a significant influential effect on the overall estimate for daytime, nighttime, and 24-h BP and that only one study 17 had a significant influential effect on the overall estimate for clinic BP.

4 | DISCUSSION

This meta-analysis shows that ambulatory BP is a stronger predictor of new-onset AF than clinic BP. Moreover, though there were slight differences across the studies regarding the impact of the ambulatory BP parameters, our results suggest that daytime, nighttime, and 24-h systolic BP are similarly associated with future AF.

To the best of our knowledge, this is the first meta-analysis in the literature evaluating this topic. Our pooled data reinforce findings from single studies.14-18

At present, it is unclear why ambulatory BP is a stronger predictor of new-onset AF than clinic BP. It could be speculated that ambulatory BP is superior to clinic BP in detecting and integrating potential mechanisms implicated in the pathogenesis of AF.19

Some studies have evaluated the impact of BP control on future occurrence of AF but results are debated.25-29 These controversial findings may partly be related to the partial ability of clinic BP to detect real BP status/control unlike ambulatory BP.8,30,31 Therefore, future research to evaluate the impact of ambulatory BP control, in comparison with clinic BP control, on the occurrence of new-onset AF might be helpful in order to find the best preventive strategy.

This study has some limitations. First, there are few studies in the literature about the topic. Second, studied populations tended to be heterogeneous including both normotensive subjects and untreated or treated hypertensive patients; however, the vast majority of individuals had hypertension. Third, the set of covariates included in multivariate analyses tended to be heterogeneous; however, the main determinants of AF were included in the various studies. In any case, despite the aforesaid limitations, the heterogeneity of the HR estimates across the studies was minimal.

| TABLE 3 | Random effects meta-analysis according to mean age at entry and prevalence of hypertension in the studied populations |
|-------------------|--------------------------|----------------|---------------------|
| **Clinic blood pressure** | Studies | Subjects/Events | Adjusted HR (95% CI) | p |
| Age <60 years | 2 | 3917/154 | 1.07 (0.94-1.22) | .59 |
| Age >60 years | 2 | 2904/199 | 1.02 (0.91-1.15) | .37 |
| HTN <50% | 1 | 2776/111 | 1.10 (0.96-1.25) | .92 (0.92-1.13) |
| HTN >50% | 3 | 4045/242 | 1.23 (1.13-1.34) | |
| **Daytime blood pressure** | Studies | Subjects/Events | Adjusted HR (95% CI) | p |
| Age <60 years | 3 | 4820/245 | 1.16 (1.05-1.27) | .41 |
| Age >60 years | 2 | 2904/199 | 1.22 (1.11-1.34) | .25 |
| HTN <50% | 2 | 3679/202 | 1.14 (1.03-1.26) | .52 |
| HTN >50% | 3 | 4045/242 | 1.23 (1.13-1.34) | |
| **Nighttime blood pressure** | Studies | Subjects/Events | Adjusted HR (95% CI) | p |
| Age <60 years | 3 | 4820/245 | 1.18 (1.08-1.28) | .90 |
| Age >60 years | 2 | 2904/199 | 1.19 (1.09-1.30) | .70 |
| HTN <50% | 2 | 3679/202 | 1.15 (1.05-1.27) | .36 |
| HTN >50% | 3 | 4045/242 | 1.20 (1.11-1.31) | |
| **24-h blood pressure** | Studies | Subjects/Events | Adjusted HR (95% CI) | p |
| Age <60 years | 3 | 4820/245 | 1.23 (1.11-1.35) | .99 |
| Age >60 years | 2 | 2904/199 | 1.23 (1.11-1.36) | .70 |
| HTN <50% | 2 | 3679/202 | 1.21 (1.09-1.35) | .36 |
| HTN >50% | 3 | 4045/242 | 1.24 (1.13-1.36) | |

Abbreviation: HTN, hypertension.
### Risk of New-Onset Atrial Fibrillation
(Per 10-mmHg Increment in Clinic Systolic Blood Pressure)

| Study name              | Statistics with study removed | Hazard ratio (95% CI) with study removed |
|-------------------------|-------------------------------|-----------------------------------------|
|                         | Point                         | Lower limit | Upper limit | Z-Value | p-Value |                        |                          |
|                         | Hazard ratio                  |            |            |         |         |                        |                          |
|                         | with study removed            |            |            |         |         |                        |                          |
| Pierdomenico et al. 2008 | 1,052                         | 0.962      | 1,152      | 1,114   | 0.265   | ![0.1, 0.2, 0.5, 1, 2, 5, 10] |
| Tikhonoff et al. 2018   | 1,020                         | 0.924      | 1,126      | 0.393   | 0.694   | ![0.1, 0.2, 0.5, 1, 2, 5, 10] |
| Matsumoto et al. 2021   | 1,085                         | 1,006      | 1,172      | 2,104   | 0.035   | ![0.1, 0.2, 0.5, 1, 2, 5, 10] |
| Coccina et al. 2021     | 1,025                         | 0.920      | 1,142      | 0.444   | 0.657   | ![0.1, 0.2, 0.5, 1, 2, 5, 10] |
|                         | 1,050                         | 0.976      | 1,131      | 1,304   | 0.192   | ![0.1, 0.2, 0.5, 1, 2, 5, 10] |

### (Per 10-mmHg Increment in Daytime Systolic Blood Pressure)

| Study name              | Statistics with study removed | Hazard ratio (95% CI) with study removed |
|-------------------------|-------------------------------|-----------------------------------------|
|                         | Point                         | Lower limit | Upper limit | Z-Value | p-Value |                        |                          |
|                         | Hazard ratio                  |            |            |         |         |                        |                          |
|                         | with study removed            |            |            |         |         |                        |                          |
| Pierdomenico et al. 2008 | 1,183                         | 1,105      | 1,267      | 4,838   | 0.000   | ![0.1, 0.2, 0.5, 1, 2, 5, 10] |
| Perklömäki et al. 2017  | 1,216                         | 1,129      | 1,310      | 5,145   | 0.000   | ![0.1, 0.2, 0.5, 1, 2, 5, 10] |
| Tikhonoff et al. 2018   | 1,192                         | 1,107      | 1,283      | 4,679   | 0.000   | ![0.1, 0.2, 0.5, 1, 2, 5, 10] |
| Matsumoto et al. 2021   | 1,185                         | 1,101      | 1,275      | 4,523   | 0.000   | ![0.1, 0.2, 0.5, 1, 2, 5, 10] |
| Coccina et al. 2021     | 1,171                         | 1,082      | 1,268      | 3,892   | 0.000   | ![0.1, 0.2, 0.5, 1, 2, 5, 10] |
|                         | 1,189                         | 1,114      | 1,270      | 5,168   | 0.000   | ![0.1, 0.2, 0.5, 1, 2, 5, 10] |

### (Per 10-mmHg Increment in Nighttime Systolic Blood Pressure)

| Study name              | Statistics with study removed | Hazard ratio (95% CI) with study removed |
|-------------------------|-------------------------------|-----------------------------------------|
|                         | Point                         | Lower limit | Upper limit | Z-Value | p-Value |                        |                          |
|                         | Hazard ratio                  |            |            |         |         |                        |                          |
|                         | with study removed            |            |            |         |         |                        |                          |
| Pierdomenico et al. 2008 | 1,172                         | 1,099      | 1,250      | 4,822   | 0.000   | ![0.1, 0.2, 0.5, 1, 2, 5, 10] |
| Perklömäki et al. 2017  | 1,191                         | 1,111      | 1,277      | 4,921   | 0.000   | ![0.1, 0.2, 0.5, 1, 2, 5, 10] |
| Tikhonoff et al. 2018   | 1,188                         | 1,108      | 1,274      | 4,848   | 0.000   | ![0.1, 0.2, 0.5, 1, 2, 5, 10] |
| Matsumoto et al. 2021   | 1,171                         | 1,092      | 1,256      | 4,430   | 0.000   | ![0.1, 0.2, 0.5, 1, 2, 5, 10] |
| Coccina et al. 2021     | 1,190                         | 1,108      | 1,279      | 4,742   | 0.000   | ![0.1, 0.2, 0.5, 1, 2, 5, 10] |
|                         | 1,182                         | 1,111      | 1,257      | 5,312   | 0.000   | ![0.1, 0.2, 0.5, 1, 2, 5, 10] |

### (Per 10-mmHg Increment in 24-hour Systolic Blood Pressure)

| Study name              | Statistics with study removed | Hazard ratio (95% CI) with study removed |
|-------------------------|-------------------------------|-----------------------------------------|
|                         | Point                         | Lower limit | Upper limit | Z-Value | p-Value |                        |                          |
|                         | Hazard ratio                  |            |            |         |         |                        |                          |
|                         | with study removed            |            |            |         |         |                        |                          |
| Pierdomenico et al. 2008 | 1,220                         | 1,133      | 1,313      | 5,278   | 0.000   | ![0.1, 0.2, 0.5, 1, 2, 5, 10] |
| Perklömäki et al. 2017  | 1,240                         | 1,145      | 1,342      | 5,300   | 0.000   | ![0.1, 0.2, 0.5, 1, 2, 5, 10] |
| Tikhonoff et al. 2018   | 1,229                         | 1,135      | 1,330      | 5,093   | 0.000   | ![0.1, 0.2, 0.5, 1, 2, 5, 10] |
| Matsumoto et al. 2021   | 1,226                         | 1,132      | 1,328      | 4,991   | 0.000   | ![0.1, 0.2, 0.5, 1, 2, 5, 10] |
| Coccina et al. 2021     | 1,232                         | 1,135      | 1,337      | 5,012   | 0.000   | ![0.1, 0.2, 0.5, 1, 2, 5, 10] |
|                         | 1,229                         | 1,145      | 1,318      | 5,740   | 0.000   | ![0.1, 0.2, 0.5, 1, 2, 5, 10] |

**Figure 3** Forest plot showing the influence of each study on the overall estimate. CI, confidence interval.
suggested that ambulatory is stronger than clinic BP in different contexts.

In conclusion, the results of this meta-analysis strongly suggest that ambulatory systolic BP prospectively predicts incident atrial fibrillation better than does clinic systolic BP and that daytime, nighttime, and 24-h systolic BP are similarly associated with future AF. In this context, further research may be needed to evaluate whether ambulatory BP lowering over time is stronger than clinic BP lowering in reducing new-onset AF.

ACKNOWLEDGMENT
Thanks are due to Tatiana Kuznetsova for providing the results of their study.

CONFLICT OF INTEREST
The authors have no conflict of interest.

AUTHOR CONTRIBUTIONS
Francesca Coccina collected the data, wrote the paper, revised the manuscript critically for important intellectual content, and gave final approval of the version to be submitted and of the revised version. Anna M. Pierdomenico collected the data, performed statistical analysis, revised the manuscript critically for important intellectual content, and gave final approval of the version to be submitted and of the revised version. Matteo De Rosa collected the data, revised the manuscript critically for important intellectual content, and gave final approval of the version to be submitted and of the revised version. Chiara Cuccurullo collected the data, revised the manuscript critically for important intellectual content, and gave final approval of the version to be submitted and of the revised version. Sante D. Pierdomenico designed the study, collected the data, performed statistical analysis, contributed to the writing of the paper, revised the manuscript critically for important intellectual content, and gave final approval of the version to be submitted and of the revised version.

ORCID
Sante D. Pierdomenico https://orcid.org/0000-0001-8038-9076

REFERENCES
1. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271:840-844.
2. Mitchell GF, Vasan RS, Keyes MJ, et al. Pulse pressure and risk of new-onset atrial fibrillation. JAMA. 2007;297:709-715.
3. Verdecchia P, Angeli F, Reboldi G. Hypertension and atrial fibrillation: doubts and certainties from basic and clinical studies. Circ Res. 2018;122:352-368.
4. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-2962.
5. Verdecchia P, Porcellati C, Schillaci G, et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension. 1994;24:793-801.
6. Yang WY, Melgarejo JD, Thijs L, et al. Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes. JAMA. 2019;322:409-420.
7. Pierdomenico SD, Pierdomenico AM, Coccina F, Lapenna D, Porreca E. Circadian blood pressure changes and cardiovascular risk in elderly-treated hypertensive patients. Hypertens Res. 2016;39:805-811.
8. Pierdomenico SD, Pierdomenico AM, Coccina F, et al. Prognostic value of masked uncontrolled hypertension. Hypertension. 2018;72:862-869.
9. Coccina F, Pierdomenico AM, Cuccurullo C, Pierdomenico SD. Prognostic value of average real variability of systolic blood pressure in elderly treated hypertensive patients. Blood Press Monit. 2019;24:179-184.
10. Coccina F, Pierdomenico AM, Cuccurullo C, et al. Prognostic value of masked uncontrolled hypertension defined by different ambulatory blood pressure criteria. Am J Hypertens. 2020;33:726-733.
11. Coccina F, Pierdomenico AM, Pizzicannella J, et al. Prognostic value of daytime and nighttime blood pressure in treated hypertensive patients according to age and sex. J Clin Hypertens. 2020;22:2014-2021.
12. Ciaroni S, Cuenod L, Bloch A. Clinical study to investigate the predictive parameters for the onset of atrial fibrillation in patients with essential hypertension. Am Heart J. 2000;139:814-819.
13. Ciaroni S, Bloch A, Lemaire MC, Fournet D, Bettoni M. Prognostic value of 24-hour ambulatory blood pressure measurement for the onset of atrial fibrillation in treated patients with essential hypertension. Am J Cardiol. 2004;94:1566-1569.
14. Pierdomenico SD, Lapenna D, Cuccurullo F. Risk of atrial fibrillation in dipper and nondipper sustained hypertensive patients. Blood Press Monit. 2008;13:193-197.
15. Perkiömäki JS, Nortamo S, Ylitalo A, Kesäniemi A, Ukkola O, Huikuri HV. Ambulatory blood pressure characteristics and long-term risk for atrial fibrillation. Am J Hypertens. 2017;30:264-270.
16. Tikhonoff V, Kuznetsova T, Thijs L, et al. Ambulatory blood pressure and long-term risk for atrial fibrillation. Heart. 2018;104:1263-1267.
17. Matsumoto K, Jin Z, Homma S, et al. Office, central and ambulatory blood pressure for predicting incident atrial fibrillation in older adults. J Hypertens. 2021;39:46-52.
18. Coccina F, Pierdomenico AM, Ianni U, et al. Ambulatory blood pressure and risk of new-onset atrial fibrillation in treated hypertensive patients. J Clin Hypertens. 2021;23:147-152.
19. Pierdomenico SD, Ianni U, De Rosa M, Coccina F. Different measures of blood pressure and incident atrial fibrillation. J Hypertens. 2021;39:38-41.
20. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-2012.
21. Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
22. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ. 1997;315:1533-1537.
23. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
24. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21:1559-1573.
25. Thomas MC, Dublin S, Kaplan RC, et al. Blood pressure control and risk of incident atrial fibrillation. Am J Hypertens. 2008;21:1111-1116.
26. Verdecchia P, Dagenais G, Healey J, et al. Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan
Randomized Assessment Study in ACE iNtolerant subjects with cardiovascular Disease studies. *J Hypertens*. 2012;30:1004-1014.

27. Watanabe T, Kawasaki M, Tanaka R, et al. Association among blood pressure control in elderly patients with hypertension, left atrial structure and function and new-onset atrial fibrillation: a prospective 2-year study in 234 patients. *Hypertens Res*. 2013;36:799-806.

28. Bhatt H, Gamboa CM, Safford MM, Soliman EZ, Glasser SP. Is there an association between the prevalence of atrial fibrillation and severity and control of hypertension? the reasons for geographic and racial differences in stroke study. *J Am Soc Hypertens*. 2016;10:578-586.

29. Rahman F, Yin X, Larson MG, et al. Trajectories of risk factors and risk of new-onset atrial fibrillation in the Framingham Heart Study. *Hypertension*. 2016;68:597-605.

30. Pierdomenico SD, Pierdomenico AM, Coccina F, Porreca E. Prognosis of masked and white coat uncontrolled hypertension detected by ambulatory blood pressure monitoring in elderly treated hypertensive patients. *Am J Hypertens*. 2017;30:1106-1111.

31. Banegas JR, Ruilope LM, de la Sierra A, et al. Clinic versus daytime ambulatory blood pressure difference in hypertensive patients: the impact of age and clinic blood pressure. *Hypertension*. 2017;69:211-219.

**SUPPORTING INFORMATION**
Additional supporting information may be found online in the Supporting Information section.

**How to cite this article:** Coccina F, Pierdomenico AM, De Rosa M, Cuccurullo C, Pierdomenico SD. Association of clinic and ambulatory blood pressure with new-onset atrial fibrillation: A meta-analysis of observational studies. *J Clin Hypertens*. 2021;23:1104–1111. [https://doi.org/10.1111/jch.14256](https://doi.org/10.1111/jch.14256)